Advertisement

Collaboration › Details
Transgene–BIO (US): investor conference, 202301 supply service Transgene attends BIO CEO + Investor Forum 2023
![]() |
Period | 2023-01-24 |
![]() |
Region | Paris |
Country | France | |
![]() |
Partner, 1st | Transgene S.A. (Euronext: TNG) |
Group | Mérieux (Group) | |
Partner, 2nd | BIO (US) (Biotechnology Innovation Organization, formerly Biotechnology Industry Organization) | |
![]() |
Product | Invest Securities BioMed Forum 2023 Paris |
Product 2 | TG4001 (MVA-HPV-IL2) (Transgene) | |
Transgene S.A.. (12/15/22). "Press Release: Transgene Announces Upcoming Investor Meetings". Strasbourg.
TRANSGENE (Paris: TNG) today announces that Management will participate in several investor events in January and February 2023, as set out below.
Transgene will meet institutional investors at the 12th Annual LifeSci Advisors Corporate Access Event and at BIO Partnering at JPM in San Francisco from January 9 to 12, 2023, in conjunction with the J.P. Morgan Healthcare conference.
The Company will also attend:
• 26th ODDO BHF Forum (virtual): January 9-10, 2023;
• Invest Securities Biomed Forum: January 24, 2023;
• Degroof Petercam’s Virtual Healthcare Conference: January 27, 2023;
• BIO CEO & Investor Forum (New York): February 6-9, 2023.
Contacts
Transgene:
Lucie Larguier
Director Corporate Communications & IR
+33 (0)3 88 27 91 04
investorrelations@transgene.fr
Media: MEDiSTRAVA Consulting
David Dible/Sylvie Berrebi/George Underwood
+44 (0)203 928 6900
transgene@medistrava.com
About Transgene
Transgene (Euronext: TNG) is a biotechnology company focused on designing and developing targeted immunotherapies for the treatment of cancer. Transgene’s programs utilize viral vector technology with the goal of indirectly or directly killing cancer cells.
The Company’s clinical-stage programs consist of two therapeutic vaccines (TG4001 for the treatment of HPV-positive cancers, and TG4050, the first individualized therapeutic vaccine based on the myvac® platform) as well as two oncolytic viruses (TG6002 for the treatment of solid tumors, and BT-001, the first oncolytic virus based on the Invir.IO™ platform).
With Transgene’s myvac® platform, therapeutic vaccination enters the field of precision medicine with a novel immunotherapy that is fully tailored to each individual. The myvac® approach allows the generation of a virus-based immunotherapy that encodes patient-specific mutations identified and selected by Artificial Intelligence capabilities provided by its partner NEC.
With its proprietary platform Invir.IO™, Transgene is building on its viral vector engineering expertise to design a new generation of multifunctional oncolytic viruses. Transgene has an ongoing Invir.IO™ collaboration with AstraZeneca.
Additional information about Transgene is available at: www.transgene.fr
Follow us on Twitter: @TransgeneSA
Record changed: 2022-12-17 |
Advertisement

More documents for Mérieux (Group)
- [1] bioMérieux S.A.. (10/19/23). "Press Release: bioMérieux Makes Strategic Investment in Oxford Nanopore". Oxford & Marcy-l’Etoile....
- [2] Oxford Biomedica plc. (9/20/23). "Press Release: Oxford Biomedica and Institut Mérieux Enter into Exclusive Negotiations with Respect to the Proposed Acquisition by Oxford Biomedica of ABL Europe". Oxford....
- [3] Transgene S.A.. (5/5/23). "Press Release: Transgene Announces New Leadership Structure to Accelerate the Development of its Innovative Immunotherapy Portfolio". Strasbourg....
- [4] bioMérieux S.A.. (4/14/23). "Press Release: Oxford Nanopore and bioMérieux to Enter into a Strategic Partnership Agreement to Develop Innovative Infectious Disease Diagnostics". Oxford & Marcy-l’Etoile....
- [5] ABL Biomanufacutring. (3/27/23). "Press Release: ABL Appoints Stéphanie Colloud as General Manager and Chief Operating Officer to Lead European Activities". Lyon....
- [6] InDevR, Inc.. (1/17/23). "Press Release: InDevR Raises $9 Million in Series B Financing and Partners with bioMérieux". Boulder, CO....
- [7] Transgene S.A.. (12/15/22). "Press Release: Transgene Announces Upcoming Investor Meetings". Strasbourg....
- [8] Mablink Bioscience S.A.S.. (10/14/22). "Press Release: Mablink Bioscience Announces a €31 Million Series A Funding Round Led by Sofinnova Partners and Mérieux Equity Partners". Lyon....
- [9] Weezion S.A.S.. (6/1/22). "Press Release: Weezion, a French MedTech Start-up, Announces Capital Investment from bioMérieux". Lyon....
- [10] bioMérieux S.A.. (3/18/22). "Press Release: bioMérieux Receives FDA 510(k) Clearance for Its VITEK MS PRIME New MALDI-TOF Mass Spectrometry Identification System". Marcy l’Étoile....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Advertisement

» top